Lilly(Eli) & Co

NYSE:LLY   1:09:49 PM EDT
306.30
+0.34 (+0.11%)
Products

FDA Approves Novel, Dual-Targeted Treatment For Type 2 Diabetes

Published: 05/13/2022 19:11 GMT
Lilly(Eli) & Co (LLY) - FDA Approves Novel, Dual-targeted Treatment for Type 2 Diabetes.
FDA Says Granted Approval of Mounjaro to Eli Lilly and Co.
FDA- Approved Mounjaro (tirzepatide) Injection to Improve Blood Sugar Control in Adults With Type 2 Diabetes, As an Addition to Diet and Exercise.
Further Company Coverage: Llyn ((reuters.
Briefs@thomsonreuters.
Com;)).